An overview of GLP-1 agonists and recent cardiovascular outcomes trials

被引：149

作者：

Sheahan, Kelsey H. ^{[1
]}

Wahlberg, Elizabeth A. ^{[2
]}

Gilbert, Matthew P. ^{[1
]}

机构：

[1] Univ Vermont, Med Ctr, Endocrinol, Burlington, VT 05401 USA

[2] Univ Vermont, Med Ctr, Internal Med, Burlington, VT USA

来源：

POSTGRADUATE MEDICAL JOURNAL | 2020年 / 96卷 / 1133期

关键词：

INTENSIVE GLUCOSE CONTROL; GLYCEMIC CONTROL; FOLLOW-UP; TYPE-2; INCRETIN; EXENATIDE;

D O I：

10.1136/postgradmedj-2019-137186

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are emerging as an important therapy to consider for patients with type 2 diabetes (T2D) given this class of treatment's ability to reduce glycated haemoglobin and their associated weight loss and low risk for hypoglycaemia. Additionally, seven cardiovascular outcomes trials (CVOTs) have been performed in the past 4 years using lixisenatide, liraglutide, semaglutide, exenatide, albiglutide, dulaglutide and oral semaglutide. All have found non-inferiority for cardiovascular outcomes, with many finding superiority of these drugs. These findings have transformed our guidelines on pharmacological treatment of T2D. This review article will discuss GLP-1 RA therapy, review the seven CVOTs reported to date and discuss the implications on current guidelines and therapies going forward.

引用

页码：156 / 161

页数：6

共 24 条

[1]

American Diabetes Association, 2017, Diabetes Care, V40, pS48

[2] Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019 [J].

Cefalu, William T. ;

Berg, Erika Gebel ;

Saraco, Mindy ;

Petersen, Matthew P. ;

Uelmen, Sacha ;

Robinson, Shamera .

DIABETES CARE, 2019, 42 :S90-S102

[3]

Cosentino F, 2019, ESC, V41, P255

[4] INCRETIN CONCEPT TODAY [J].

CREUTZFELDT, W .

DIABETOLOGIA, 1979, 16 (02) :75-85

[5] Impact of Diabetes on Cardiovascular Disease: An Update [J].

de Mattos Matheus, Alessandra Saldanha ;

Monteiro Tannus, Lucianne Righeti ;

Cobas, Roberta Arnoldi ;

Sousa Palma, Catia C. ;

Negrato, Carlos Antonio ;

Gomes, Marilia de Brito .

INTERNATIONAL JOURNAL OF HYPERTENSION, 2013, 2013

[6] Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes [J].

DeFronzo, RA ;

Ratner, RE ;

Han, J ;

Kim, DD ;

Fineman, MS ;

Baron, AD .

DIABETES CARE, 2005, 28 (05) :1092-1100

[7] The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes [J].

Drucker, Daniel J. ;

Nauck, Michael A. .

LANCET, 2006, 368 (9548) :1696-1705

[8] PLASMA INSULIN RESPONSE TO ORAL + INTRAVENOUS GLUCOSE ADMINISTRATION [J].

ELRICK, H ;

HLAD, CJ ;

ARAI, Y ;

STIMMLER, L .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1964, 24 (10) :1076-+

[9]

Food and Drug Administration, 2008, DIAB MELL EV CARD RI

[10]

Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743

← 1 2 3 →